title: Developmental Toxicity Studies with Pregabalin in Rats: Significance of Alterations in Skull Bone Morphology.
abstract: Pregabalin was administered to pregnant Wistar rats during organogenesis to evaluate potential developmental toxicity. In an embryo-fetal development study, compared with controls, fetuses from pregabalin-treated rats exhibited increased incidence of jugal fused to maxilla (pregabalin 1250 and 2500 mg/kg) and fusion of the nasal sutures (pregabalin 2500 mg/kg). The alterations in skull development occurred in the presence of maternal toxicity (reduced body weight gain) and developmental toxicity (reduced fetal body weight and increased skeletal variations), and were initially classified as malformations. Subsequent investigative studies in pregnant rats treated with pregabalin during organogenesis confirmed the advanced jugal fused to maxilla, and fusion of the nasal sutures at cesarean section (gestation day/postmating day [PMD] 21) in pregabalin-treated groups. In a study designed to evaluate progression of skull development, advanced jugal fused to maxilla and fusion of the nasal sutures was observed on PMD 20-25 and PMD 21-23, respectively (birth occurs approximately on PMD 22). On postnatal day (PND) 21, complete jugal fused to maxilla was observed in the majority of control and 2500 mg/kg offspring. No treatment-related differences in the incidence of skull bone fusions occurred on PND 21, indicating no permanent adverse outcome. Based on the results of the investigative studies, and a review of historical data and scientific literature, the advanced skull bone fusions were reclassified as anatomic variations. Pregabalin was not teratogenic in rats under the conditions of these studies.
authors.affiliation: Pfizer Worldwide Research and Development, Drug Safety Research and Development, Groton, Connecticut.
authors.forename: Dennis C
authors.initials: DC
authors.lastname: Morse
authors.affiliation: Toxicology Solutions Consulting LLC, Leeds, Utah.
authors.forename: Judith W
authors.initials: JW
authors.lastname: Henck
authors.affiliation: Pfizer Worldwide Research and Development, Drug Safety Research and Development, Andover, Massachusetts.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Bailey
mesh_terms: D000818:Animals; D002585:Cesarean Section; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian / Q000187:drug effects; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D020567:Fetal Weight / Q000187:drug effects; D005333:Fetus / Q000187:drug effects; D018811:Maternal Exposure; D019055:No-Observed-Adverse-Effect Level; D038081:Organogenesis / Q000187:drug effects*; D000069583:Pregabalin / Q000008:administration & dosage / Q000633:toxicity*; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D012886:Skull / Q000187:drug effects* / Q000196:embryology*; D013723:Teratogens / Q000633:toxicity; D018675:Toxicity Tests
chemical_list: D013723:Teratogens; D000069583:Pregabalin
keywords: developmental toxicity; pregabalin; teratology